Cargando…

FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology

Detalles Bibliográficos
Autores principales:	Russell, Elizabeth S., Aubrun, Elodie, Moga, Daniela C., Guedes, Sandra, Camelo Castillo, Wendy, Hardy, Janet R., Cole, J. Alexander, Jagun, Oladayo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225256/ https://www.ncbi.nlm.nih.gov/pubmed/37251002 http://dx.doi.org/10.1017/cts.2023.515

Ejemplares similares

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Perspectives on the FDA Draft Guidances for Use of Adipose Tissue
por: Johnson, Martin L., et al.
Publicado: (2017)

The Challenges and Opportunities of Pharmacoepidemiology in Bone Diseases
por: Alarkawi, Dunia, et al.
Publicado: (2018)

Editorial: Women in pharmacoepidemiology: 2021
por: Lopes, Luciane Cruz, et al.
Publicado: (2023)

Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
por: Harrison, John E.
Publicado: (2018)

Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
por: de Vlieger, Jon S. B., et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

Pharmacovigilance and Pharmacoepidemiology
Publicado: (2008)

Understanding pharmacoepidemiology
Publicado: (2011)

Pharmacoepidemiology: An Overview
por: Sabaté, Mònica, et al.
Publicado: (2023)

Control yourself: ISPE‐endorsed guidance in the application of self‐controlled study designs in pharmacoepidemiology
por: Cadarette, Suzanne M., et al.
Publicado: (2021)

FDA perspectives on potential microarray-based clinical diagnostics
por: Težak, Živana, et al.
Publicado: (2006)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges
por: Lai, Edward Chia-Cheng, et al.
Publicado: (2018)

The FDA’s Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
por: Marks, Peter
Publicado: (2019)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Translational research of one dynamic hip screw system—from the SCI to the FDA
por: Kao, Hung-Chan, et al.
Publicado: (2016)

The FDA-Approved Essure Device Counseling Order Fails to Promote Patient Empowerment
por: Gunn, Christine M., et al.
Publicado: (2019)

FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation
por: Milko, Laura V., et al.
Publicado: (2019)

Dose Selection in a Pandemic: A Framework Informed by the FDA Animal Rule
por: Wu, Kunyi, et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

Opportunities and challenges with stem cell-based embryo models
por: Rossant, Janet, et al.
Publicado: (2021)

The Promotion of Data Sharing in Pharmacoepidemiology
por: Sethi, Nayha
Publicado: (2014)

The use of narrative electronic prescribing instructions in pharmacoepidemiology: A scoping review for the International Society for Pharmacoepidemiology
por: Romanelli, Robert J., et al.
Publicado: (2021)

The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
por: Niazi, Sarfaraz K
Publicado: (2023)

Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations
por: Wong, Jenna, et al.
Publicado: (2022)

Better Guidance Is Welcome, but without Blinders
por: Peters, David H., et al.
Publicado: (2012)

Guidance for publishing qualitative research in informatics
por: Ancker, Jessica S, et al.
Publicado: (2021)

Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop
por: Zhang, X, et al.
Publicado: (2017)

Feedback on the FDA's February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures
por: Bradley, Clare
Publicado: (2006)

Paxlovid(TM) Information From FDA and Guidance for AES Members
por: Cokley, Jon A., et al.
Publicado: (2022)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Mendelian Randomization Studies Promise to Shorten the Journey to FDA Approval
por: Roberts, Robert
Publicado: (2018)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK
por: Wagner, C, et al.
Publicado: (2015)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Pharmacoepidemiological aspects of outpatient pain medication
por: Zebedin, Eva-Maria, et al.
Publicado: (2011)

Evaluation of Medication-mediated Effects in Pharmacoepidemiology
por: Tchetgen Tchetgen, Eric J., et al.
Publicado: (2017)

Translating Coverage Gains into Health Gains for All Women and Children: The Quality Care Opportunity
por: Graham, Wendy J., et al.
Publicado: (2013)

Understanding axon guidance: attraction, repulsion, and statistical physics
por: Wadsworth, William G.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_efp1191jdh5d7u70t05odndcv5